Medical News

RSS

Overcoming resistance - new options for the treatment of ovarian cancer

Research on the development of a new therapeutic agent for the treatment of particularly aggressive ovarian cancer has produced some very promising initial findings. In laboratory tests, scientists have succeeded in reducing the resistance of the tumour cells to a natural resistance mechanism with the help of a monoclonal antibody. The results of this project, which was funded by the Austrian Science Fund FWF, have just been published. The project also succeeded in establishing a hitherto unknown connection between so-called "natural killer cells" and the regulated death of cancer cells.

12 Apr 2010

RXi Pharmaceuticals, Mirna Therapeutics form microRNA research collaboration

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced today that it has entered into a research collaboration with Mirna Therapeutics (Austin, TX), to determine the utility of combining RXi's proprietary rxRNA™ technology with Mirna's microRNA mimics as potential therapeutics in oncology. The parties will each contribute technology and resources to the collaboration to generate and evaluate novel microRNA compounds.

12 Apr 2010

COBRA subsidy extension Senate vote expected today

Congressional Quarterly: A 65 percent subsidy that helped laid-off Americans pay for their COBRA health insurance premiums expired March 31, just before the Congressional recess. Now, one of the first orders of business is voting on legislation that would extend that subsidy. "With 15 million Americans unemployed, some advocates for the jobless say Congress should not only be extending the COBRA subsidies but expanding them — either with more-generous subsidies or by changing the law to make more people eligible."

12 Apr 2010

Mylan Pharmaceuticals' ANDA for generic Wellbutrin SR receives FDA final approval

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Bupropion Hydrochloride Extended-Release Tablets USP, (SR), 100 mg, 150 mg and 200 mg, the generic version of GlaxoSmithKline's antidepressant Wellbutrin SR®.

12 Apr 2010

More states coping with primary care shortage

In a major feature, The Tennessean reports that the "nation is short 16,663 primary care doctors, and by 2025 that number will reach nearly 140,000, according to the American Academy of Family Physicians."

12 Apr 2010

FDA approves Mylan Pharmaceuticals' ANDA for generic Hyzaar

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Losartan Potassium and Hydrochlorothiazide (HCTZ) Tablets 100 mg/12.5 mg, the generic version of Merck and Co., Inc.'s antihypertensive Hyzaar®.

12 Apr 2010

Diasorin migrates to Orange Business Services' Business VPN solution

Diasorin S.p.A., an international player in the market of in vitro diagnostics based in Saluggia (Vercelli, Italy), has migrated to Business VPN, a fully-managed, secure, global IP infrastructure from Orange Business Services connecting 12 locations in Europe, the Americas and Asia.

12 Apr 2010

Drinking during adolescence increases risk of benign breast disease in young women

Girls and young women who drink alcohol increase their risk of benign (noncancerous) breast disease, says a study by researchers at Washington University School of Medicine in St. Louis and Harvard University. Benign breast disease increases the risk for developing breast cancer.

12 Apr 2010

With health debate resolved, investors see continued health sector growth

After months of uncertainty during the health-overhaul debate, financial analysts and mutual fund managers are feeling more stable and seeing upsides from the new law, The New York Times reports. "There does not seem to be any onerous cost control," one analyst said. Another added, "There is just an expansion of coverage [and] not a lot of surprises."

12 Apr 2010

Hospira's proposed merger and loan agreements better than MPI's, says Javelin Pharmaceuticals

Javelin Pharmaceuticals, Inc. announced today that it had received a binding offer from Hospira, Inc. and its wholly-owned subsidiary, Discus Acquisition Corporation ("Discus"), to enter into a merger agreement, a loan and security agreement and intellectual property security agreements whereby Discus will, subject to certain conditions, commence an all cash tender offer to acquire all of the outstanding shares of Javelin at a per share price of $2.20.

12 Apr 2010

CPEX Pharmaceuticals files definitive proxy materials with SEC, mails open letter to shareholders

CPEX Pharmaceuticals, Inc. today announced that it has filed definitive proxy materials with the Securities and Exchange Commission (SEC) for its 2010 Annual Meeting of Stockholders. The Company has nominated Robert Forrester, a highly qualified independent director candidate, for election to the Board of Directors at the meeting.

12 Apr 2010

Biomedical Systems selects Global 360's Process360 BPM suite for improving report, image communication

Global 360, a leading provider of Process and Document Management solutions, today announced that Biomedical Systems, a global leader in centralized diagnostic testing for the pharmaceutical and medical device industry, has chosen Global 360 to improve how critical reports and images are communicated and reported to its customers. In the process, the company will also save thousands on courier costs, satisfy a "going green" initiative, and mitigate risk, helping satisfy auditors and regulators.

12 Apr 2010

Angiochem to highlight oncology program data at 101st American Association for Cancer Research meeting

Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier through LRP targeting, announced today that preclinical data on two of its oncology programs, ANG1005 and ANG1007, for the treatment of brain cancers, as well as data demonstrating the utility of Angiochem's EPiC platform to achieve efficient penetration rates in the brain and in cancer tumor tissue, will be highlighted at the 101st Annual meeting of the American Association for Cancer Research 2010.

12 Apr 2010

Today's Opinions and Editorials: Immigration as a solution; Health care comparative shopping; and Medicare Advantage competitive pricing

Forty years ago there were five workers for every retiree. Now there are three. Within a couple of decades, there will be only two workers per retiree. There's no way just two workers will be able or willing to pay enough payroll taxes to keep benefits flowing to every retiree (Robert Reich, 4/11).

12 Apr 2010

XenoPort to present arbaclofen placarbil, XP13512 trial data at 62nd American Academy of Neurology meeting

XenoPort announced today that new data from clinical trials of its product candidates arbaclofen placarbil and XP13512 (gabapentin enacarbil) will be presented at the 62nd Annual American Academy of Neurology meeting in Toronto, Ontario.

12 Apr 2010

CHI selects RelayHealth RevRunner healthcare solution

RelayHealth announced today that Catholic Health Initiatives (CHI), the nation's second-largest Catholic healthcare system, has chosen RelayHealth RevRunner to verify patient eligibility for healthcare benefits.

12 Apr 2010

EHSI expects new iPhone 4.0 OS to benefit MedAnywhere application

Emerging Healthcare Solutions, Inc. enthusiastically welcomed a highly anticipated report that Apple has unveiled the new iPhone 4.0 Operating System, which the Company believes will greatly benefit the MedAnywhere medical app currently in development. Specifically, new multitasking ability can be applied so that a physician can initiate patient monitoring subroutines without having to exit the MedAnywhere live communications portal.

12 Apr 2010

Epix Pharmaceuticals' MRI imaging intellectual properties to be auctioned on May 28, 2010

Joseph F. Finn, Jr., C.P.A., Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix"), announced today that the MRI imaging intellectual properties will be auctioned on May 28, 2010. The assets of Epix were transferred to him on July 20, 2009 and he is liquidating them for the benefit of Epix creditors. He recently reached an agreement with Bayer Schering Pharma that permits the sale of the MRI imaging programs.

12 Apr 2010

Verizon Wireless, BL Healthcare to jointly trial solutions for delivery of remote healthcare applications

Verizon Wireless today announced an initiative with BL Healthcare and a number of customers and third-party providers to jointly trial next-generation solutions for the delivery of remote healthcare applications and services to patients. This initiative will provide a unique approach for addressing issues associated with access to quality healthcare and rising healthcare costs.

12 Apr 2010

IntriCon to launch Scenic DSP amplifier at AudiologyNOW!

IntriCon Corporation, a designer, developer, manufacturer and distributor of body-worn medical and electronics devices, will unveil its Scenic™ DSP amplifier at AudiologyNOW!, the annual convention of the American Academy of Audiology, being held April 14-17, 2010, at the San Diego Convention Center.

12 Apr 2010

Medical News

Overcoming resistance - new options for the treatment of ovarian cancer

RXi Pharmaceuticals, Mirna Therapeutics form microRNA research collaboration

COBRA subsidy extension Senate vote expected today

Mylan Pharmaceuticals' ANDA for generic Wellbutrin SR receives FDA final approval

More states coping with primary care shortage

FDA approves Mylan Pharmaceuticals' ANDA for generic Hyzaar

Diasorin migrates to Orange Business Services' Business VPN solution

Drinking during adolescence increases risk of benign breast disease in young women

With health debate resolved, investors see continued health sector growth

Hospira's proposed merger and loan agreements better than MPI's, says Javelin Pharmaceuticals

CPEX Pharmaceuticals files definitive proxy materials with SEC, mails open letter to shareholders

Biomedical Systems selects Global 360's Process360 BPM suite for improving report, image communication

Angiochem to highlight oncology program data at 101st American Association for Cancer Research meeting

Today's Opinions and Editorials: Immigration as a solution; Health care comparative shopping; and Medicare Advantage competitive pricing

XenoPort to present arbaclofen placarbil, XP13512 trial data at 62nd American Academy of Neurology meeting

CHI selects RelayHealth RevRunner healthcare solution

EHSI expects new iPhone 4.0 OS to benefit MedAnywhere application

Epix Pharmaceuticals' MRI imaging intellectual properties to be auctioned on May 28, 2010

Verizon Wireless, BL Healthcare to jointly trial solutions for delivery of remote healthcare applications

IntriCon to launch Scenic DSP amplifier at AudiologyNOW!

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Latest News